Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
43,016,906
-
Shares change
-
+4,876,068
-
Total reported value, excl. options
-
$867,295,836
-
Value change
-
+$98,827,896
-
Put/Call ratio
-
4.21%
-
Number of buys
-
85
-
Number of sells
-
-29
-
Price
-
$20.16
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2020
136 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2020.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43,016,906 shares
of 62,162,717 outstanding shares and own 69.2% of the company stock.
Largest 10 shareholders include FMR LLC (6,452,764 shares), BVF INC/IL (4,273,588 shares), RTW INVESTMENTS, LP (3,650,069 shares), Consonance Capital Management LP (2,729,709 shares), BlackRock Inc. (2,591,711 shares), Johnson & Johnson Innovation - JJDC, Inc. (2,449,183 shares), FARALLON CAPITAL MANAGEMENT LLC (2,425,000 shares), VANGUARD GROUP INC (2,017,637 shares), STATE STREET CORP (1,484,316 shares), and BAKER BROS. ADVISORS LP (1,436,192 shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.